Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CBMG
- CUSIP: N/A
- Web: www.cellbiomedgroup.com
Capitalization:- Market Cap: $139.33 million
- Outstanding Shares: 14,290,000
Average Prices:- 50 Day Moving Avg: $8.20
- 200 Day Moving Avg: $10.25
- 52 Week Range: $5.05 - $15.68
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.27
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $237,864.00
- Price / Sales: 585.74
- Book Value: $4.29 per share
- Price / Book: 2.27
Profitability:- EBIDTA: ($22,090,000.00)
- Net Margins: -12,672.27%
- Return on Equity: -38.40%
- Return on Assets: -37.15%
Debt:- Current Ratio: 17.66%
- Quick Ratio: 17.66%
Misc:- Average Volume: 67,519 shs.
- Beta: 2.66
- Short Ratio: 2.05
Frequently Asked Questions for Cellular Biomedicine Group (NASDAQ:CBMG)
What is Cellular Biomedicine Group's stock symbol?
Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."
How will Cellular Biomedicine Group's stock buyback program work?
Cellular Biomedicine Group announced that its board has authorized a share buyback program on Sunday, June 4th 2017, which permits the company to repurchase $10,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.
How were Cellular Biomedicine Group's earnings last quarter?
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) issued its quarterly earnings results on Tuesday, March, 14th. The company reported ($0.43) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.43). The business had revenue of $0.06 million for the quarter. Cellular Biomedicine Group had a negative return on equity of 38.40% and a negative net margin of 12,672.27%. View Cellular Biomedicine Group's Earnings History.
When will Cellular Biomedicine Group make its next earnings announcement?
Where is Cellular Biomedicine Group's stock going? Where will Cellular Biomedicine Group's stock price be in 2017?
1 analysts have issued 1 year target prices for Cellular Biomedicine Group's shares. Their predictions range from $18.00 to $18.00. On average, they expect Cellular Biomedicine Group's stock price to reach $18.00 in the next year. View Analyst Ratings for Cellular Biomedicine Group.
Are investors shorting Cellular Biomedicine Group?
Cellular Biomedicine Group saw a decrease in short interest in the month of June. As of June 30th, there was short interest totalling 228,602 shares, a decrease of 60.4% from the June 15th total of 577,279 shares. Based on an average trading volume of 155,602 shares, the short-interest ratio is presently 1.5 days. Currently, 2.2% of the shares of the company are sold short.
Who are some of Cellular Biomedicine Group's key competitors?
Some companies that are related to Cellular Biomedicine Group include Immune Design Corp. (IMDZ), DURECT Corporation (DRRX), Catalyst Pharmaceuticals (CPRX), Akebia Therapeutics (AKBA), Circassia Pharmaceuticals PLC (CIR), Oxford BioMedica plc (OXB), Pieris Pharmaceuticals (PIRS), Chimerix (CMRX), Stemline Therapeutics (STML), Clearside Biomedical (CLSD), Cempra (CEMP), uniQure N.V. (QURE), CymaBay Therapeutics (CBAY), ObsEva SA (OBSV), Ovid Therapeutc (OVID), Tocagen (TOCA), Foamix Pharmaceuticals (FOMX) and Gemphire Therapeutics (GEMP).
Who are Cellular Biomedicine Group's key executives?
Cellular Biomedicine Group's management team includes the folowing people:
- Terry A. Belmont, Chairman of the Board
- Bizuo Liu, Chief Executive Officer, Interim Chief Financial Officer, Secretary
- Xia Meng, Chief Operating Officer
- Yihong Yao Ph.D., Chief Scientific Officer
- Richard L. Wang Ph.D., Chief Operation Officer
- Zhou Hansheng, Director
- Gerardus A. Hoogland, Director
- Gang Jacky Ji, Director
- Hansheng Zhou, Non-Executive Director
- Chun Kwok Alan Au, Independent Director
How do I buy Cellular Biomedicine Group stock?
Shares of Cellular Biomedicine Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellular Biomedicine Group's stock price today?
One share of Cellular Biomedicine Group stock can currently be purchased for approximately $9.75.
MarketBeat Community Rating for Cellular Biomedicine Group (NASDAQ CBMG)MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cellular Biomedicine Group (NASDAQ:CBMG) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $18.00 (84.62% upside) |
Analysts' Ratings History for Cellular Biomedicine Group (NASDAQ:CBMG)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/15/2017 | Maxim Group | Set Price Target | Buy | $18.00 | High |  |
(Data available from 7/25/2015 forward)
Earnings History for Cellular Biomedicine Group (NASDAQ:CBMG)Earnings History by Quarter for Cellular Biomedicine Group (NASDAQ CBMG)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2017 | | | | | | | N/A | |
| 3/14/2017 | Q4 2016 | ($0.43) | ($0.43) | | $0.06 million | View | N/A | |
| 8/9/2016 | Q216 | | ($0.52) | | $0.07 million | View | N/A | |
| 3/14/2016 | Q415 | ($0.42) | ($0.43) | $1.50 million | $0.62 million | View | N/A | |
| 11/13/2015 | Q3 | ($0.43) | ($0.44) | | $0.63 million | View | N/A | |
| 8/14/2015 | Q215 | ($0.37) | ($0.44) | | $0.66 million | View | N/A | |
| 5/18/2015 | Q115 | ($0.40) | ($0.39) | | $0.60 million | View | N/A | |
| 3/31/2015 | | ($0.32) | ($0.57) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cellular Biomedicine Group (NASDAQ:CBMG)Current Year EPS Consensus Estimate: $-1.80 EPS
Next Year EPS Consensus Estimate: $-1.85 EPS
Dividend History for Cellular Biomedicine Group (NASDAQ:CBMG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cellular Biomedicine Group (NASDAQ:CBMG)Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 9.87%
Insider Trades by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/6/2017 | Tony Liu | CEO | Buy | 10,000 | $6.83 | $68,300.00 | |
| 2/22/2016 | Andrew K Chan | SVP | Sell | 1,307 | $18.22 | $23,813.54 | |
| 2/17/2016 | Andrew K. Chan | SVP | Sell | 1,516 | $17.76 | $26,924.16 | |
| 1/21/2016 | Andrew K. Chan | SVP | Sell | 2,812 | $12.90 | $36,274.80 | |
| 12/21/2015 | Andrew K. Chan | SVP | Sell | 12,812 | $21.94 | $281,095.28 | |
| 11/23/2015 | Andrew K. Chan | SVP | Sell | 5,332 | $20.64 | $110,052.48 | |
| 10/21/2015 | Wei (William) Cao | CEO | Sell | 20,000 | $19.59 | $391,800.00 | |
| 10/20/2015 | Andrew K. Chan | SVP | Sell | 5,215 | $20.20 | $105,343.00 | |
| 9/21/2015 | Andrew K. Chan | SVP | Sell | 27,927 | $20.80 | $580,881.60 | |
| 12/23/2014 | Pak To Leung | Major Shareholder | Sell | 142,857 | $14.00 | $1,999,998.00 | |
| 6/26/2014 | David Bolocan | Director | Buy | 10,000 | $5.00 | $50,000.00 | |
| 5/22/2014 | Tony Liu | CFO | Buy | 100,000 | $5.00 | $500,000.00 | |
| 7/23/2013 | Keith Wong | Director | Sell | 320,050 | $0.13 | $41,606.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cellular Biomedicine Group (NASDAQ:CBMG)
Latest Headlines for Cellular Biomedicine Group (NASDAQ:CBMG)
| Source: |
|
| Date | Headline |
|---|
 | Cellular Biomedicine Group, Inc. (CBMG) Short Interest Down 60.4% in June
www.americanbankingnews.com - July 16 at 7:06 AM |
 | ETFs with exposure to Cellular Biomedicine Group, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 5:59 PM |
 | Cellular Biomedicine Group (CBMG) Annoucnes Dr. Xia Meng as New COO to Lead Commercialization of the Company’s CAR-T and Stem Cell Products
www.streetinsider.com - June 26 at 9:53 PM |
| ProNAi Therapeutics (SRRA) versus Cellular Biomedicine Group (CBMG) Financial Analysis
www.americanbankingnews.com - June 26 at 6:48 PM |
| Cellular Biomedicine Group (CBMG) Appoints Dr. Xia Meng as Chief Operating Officer to Lead Commercialization of the Company’s CAR-T and Stem Cell Products
finance.yahoo.com - June 26 at 4:51 PM |
| Zacks: Cellular Biomedicine Group, Inc. (CBMG) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - June 21 at 6:15 PM |
| Cellular Biomedicine Group Appoints Michael A. Caligiuri, MD as Chair of External Advisory Board
finance.yahoo.com - June 20 at 7:15 AM |
| Cellular Biomedicine Group Inc (CBMG) CEO Tony Liu Acquires 10,000 Shares
www.americanbankingnews.com - June 7 at 1:26 PM |
| ETFs with exposure to Cellular Biomedicine Group, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 4:07 PM |
| Cellular Biomedicine Group (CBMG) Board of Directors Declares Stock Repurchase Program
www.americanbankingnews.com - June 4 at 11:08 AM |
| Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 5:38 PM |
 | BRIEF-Cellular Biomedicine Group announces stock repurchase program
www.reuters.com - June 1 at 9:43 PM |
| Cellular Biomedicine Group (CBMG) Announces $10M Buyback Program
www.streetinsider.com - June 1 at 9:43 PM |
| Cellular Biomedicine Group (CBMG) Announces Stock Repurchase Program
finance.yahoo.com - June 1 at 4:43 PM |
| Cellular Biomedicine Group Inc (CBMG) Given $18.00 Average Target Price by Analysts
www.americanbankingnews.com - May 29 at 4:34 PM |
| Cellular Biomedicine Group Inc (CBMG) Short Interest Up 3.3% in April
www.americanbankingnews.com - May 23 at 7:04 AM |
 | Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20
www.nasdaq.com - May 19 at 8:52 AM |
| Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody” in Conjunction with 2017 ASCO Annual Meeting
finance.yahoo.com - May 19 at 8:52 AM |
| Cellular Biomedicine Group Inc (CBMG) Given a $18.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - May 15 at 5:02 PM |
| BRIEF-Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trial
www.reuters.com - May 15 at 3:53 PM |
| Cellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma (NHL)
finance.yahoo.com - May 15 at 11:44 AM |
| Maxim Group Analysts Give Cellular Biomedicine Group Inc (CBMG) a $18.00 Price Target
www.americanbankingnews.com - May 10 at 12:16 AM |
| BRIEF-Cellular Biomedicine Q1 net loss per share $0.43
www.reuters.com - May 8 at 9:06 PM |
 | Cellular Biomedicine reports 1Q loss
marketbeat.com - May 8 at 5:36 PM |
| Cellular Biomedicine Group Reports First Quarter 2017 Financial Results and Provides Business Highlights
finance.yahoo.com - May 8 at 4:05 PM |
| Cellular Biomedicine Group (CBMG) Getting Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - May 3 at 12:20 AM |
| Cellular Biomedicine Group Announces Results of 2017 Annual Meeting of Stockholders
finance.yahoo.com - May 1 at 4:10 PM |
| Cellular Biomedicine Group (CBMG) Earns Media Sentiment Rating of 0.48
www.americanbankingnews.com - April 28 at 11:54 AM |
| Cellular Biomedicine Group (CBMG) Getting Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 25 at 10:32 AM |
| Cellular Biomedicine Group (CBMG) Given Coverage Optimism Score of 0.46
www.americanbankingnews.com - April 18 at 1:38 PM |
| Cellular Biomedicine Group (CBMG) Receiving Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 15 at 9:21 AM |
| GE Collaborates with CBMG to Enhance Healthcare Portfolio
finance.yahoo.com - April 11 at 10:05 AM |
| Cellular Biomedicine and GE Healthcare Ink Pact
finance.yahoo.com - April 10 at 4:07 PM |
| Maxim Group Reiterates Buy Rating for Cellular Biomedicine Group Inc (CBMG)
www.americanbankingnews.com - April 10 at 1:42 PM |
| Cellular Biomedicine Group (CBMG) Announces Completion of Wuxi GMP Facility Expansion
finance.yahoo.com - March 30 at 4:35 PM |
 | Is Cellular Biomedicine Group A Buy?
seekingalpha.com - March 26 at 10:49 AM |
| Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders
finance.yahoo.com - March 21 at 9:15 AM |
| BRIEF-Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31
www.reuters.com - March 15 at 2:06 AM |
| CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K/A, Annual Report
biz.yahoo.com - March 14 at 9:04 PM |
| CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 14 at 11:12 AM |
 | Cellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational Progress
us.rd.yahoo.com - March 14 at 11:12 AM |
 | Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market
www.benzinga.com - March 4 at 1:35 AM |
| Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin™ Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S.
us.rd.yahoo.com - March 1 at 10:29 AM |
| Cellular Biomedicine Group (CBMG) Presents at 19th Annual BIO CEO & Investor Conference
seekingalpha.com - February 15 at 2:52 AM |
| Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February
www.nasdaq.com - February 8 at 3:18 AM |
| Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February 13, 2017
feeds.benzinga.com - February 7 at 9:19 AM |
| Cellular Biomedicine Group (CBMG) Gains Approval to Commence Phase I Trial for C-CAR011 in China
www.streetinsider.com - January 9 at 10:21 PM |
| Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult
www.nasdaq.com - January 9 at 10:21 PM |
| Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China
us.rd.yahoo.com - January 9 at 9:00 AM |
| Cellular Biomedicine Group (CBMG) to Present at the 9th Annual Biotech Showcase in San Francisco
finance.yahoo.com - January 4 at 5:11 PM |
Cellular Biomedicine Group (CBMG) Chart for Tuesday, July, 25, 2017
